Myasthenia gravis: a real disease, and a nervous system that can add noise on top of it.

MG weakens muscles through a measurable autoimmune attack. It also frightens people, and fear has symptoms of its own. Telling the two apart matters.

This page is about understanding the condition and the role the brain and nervous system can play in it. It is not a diagnosis. Your own clinicians know your case.

Getting the diagnosis right comes first

Myasthenia gravis, usually shortened to MG, is an autoimmune disorder of the junction between nerve and muscle. The immune system makes antibodies, most often against the acetylcholine receptor, that block the signal telling a muscle to contract. The result is weakness that is characteristically fatigable: it gets worse the more a muscle is used and better after rest. It commonly starts in the eye muscles, causing drooping eyelids and double vision, and can spread to the face, throat, neck, limbs and the muscles of breathing. A myasthenic crisis, in which breathing muscles fail, is a medical emergency.

MG is a structural disease with clear criteria. Diagnosis rests on the pattern of fatigable weakness, blood tests for antibodies, electrical tests of nerve-to-muscle transmission (repetitive stimulation and single-fibre EMG), and historically the edrophonium (Tensilon) test, in which a short-acting drug briefly restores strength. Treatment includes drugs that boost the nerve signal, immune-suppressing medication, newer targeted therapies, and sometimes removal of the thymus gland. This is specialist neurology, and nothing in this article replaces it.

The neuroplastic contribution

Neuroplastic symptoms are real symptoms generated by learned pathways in the brain and nervous system rather than by damage or disease in the body. They include pain, fatigue, dizziness, tingling and a sense of weakness that the nervous system produces as a protective signal when it perceives threat. They are not imaginary and not 'all in your head', and they can change because the brain is plastic. They can exist on their own, and they can exist on top of a structural disease.

The ATNS Index of Neuroplastic Symptoms is clear and worth quoting in spirit: MG is not due to neuroplastic symptoms. The index then makes two further observations that matter to someone living with MG.

• Stress and the immune system. As an autoimmune disorder, MG may be influenced by stress through the psychoneuroimmune system, the two-way traffic between the brain, the stress hormones and the immune response. Stress levels may therefore be linked to symptoms getting worse or easing. This is about the disease itself being modulated by stress, not about symptoms being neuroplastic.
• Fear as a second engine. Having MG can cause intense fear and worry, which can in turn activate neuroplastic symptoms. A person with MG may then experience two things at once: genuine myasthenic weakness, and nervous-system symptoms (exhaustion, heaviness, breathlessness, tingling, pain) generated by the threat system.

The practical consequence is that someone with well-controlled MG who still feels dreadful may be dealing with the second engine as much as the first. That is not a reason to doubt the MG. It is a reason to address both.

What the research shows

The research supports both of the ATNS index's observations, within limits. A systematic review and meta-analysis of depression and anxiety in MG found that about 36 percent of people with MG have depression and about 33 percent have anxiety, far above general population rates. A review of psychiatric comorbidity in MG notes that physical and emotional stressors may induce myasthenic exacerbations, and proposes that prolonged stress, anxiety and depression can affect immune function through the stress-hormone axis, the sympathetic nervous system and inflammatory pathways. The authors present this as a hypothesis rather than settled fact.

A 2025 study combining clinical data with Mendelian randomization, a genetic method for probing cause and effect, found that MG severity scores were associated with anxiety and depression, but found no genetic evidence that MG itself causes anxiety or depression. One reading is that the emotional burden comes from living with the disease, its unpredictability and its treatment, rather than from the antibodies directly. A separate cohort found that lower quality of life and weaker social support, not the formal MG severity grade, were the independent predictors of psychological distress.

Signs the brain may be part of the picture

• Your neurologist says the MG is well controlled, but you feel exhausted, heavy or unwell most of the time.
• Symptoms flare with worry, conflict or poor sleep as much as with physical exertion.
• You have symptoms MG does not usually cause, such as widespread pain, tingling, dizziness or a racing heart, with normal tests.
• Fear of a crisis shapes your daily decisions more than your actual strength does.

A solution that addresses it

For the neuroplastic layer, pain and symptom reprocessing is the approach built for it. It combines education about neuroplastic symptoms, somatic tracking (observing sensations such as heaviness with curiosity rather than alarm), reducing fear and the sense of threat, a graded return to activity within the limits your neurologist sets, emotional awareness and expression, and acceptance and commitment skills, which our ACT basics guide introduces. Trained clinicians deliver it, and digital programs are making it more accessible. It sits alongside MG treatment and never replaces it.

Cindra is a daily AI companion built around these approaches, with daily check-ins, short practices and plain-language lessons for people whose symptoms have a neuroplastic component. If you are living with MG and want support with the fear and the nervous-system symptoms that ride alongside it, you can join the waitlist.

What to do next

1. Keep MG treatment exactly as prescribed. Never adjust or stop medication without your neurologist. Seek emergency care for any difficulty breathing, trouble swallowing saliva, or rapidly worsening weakness; these can signal a myasthenic crisis.
2. Report new or unusual symptoms to your neurologist first. Let them decide whether a symptom is MG, a medication effect, or something else before assuming it is neuroplastic.
3. Then ask about the second engine. 'Could fear and stress be adding symptoms on top of my MG?' The ATNS index says they can.
4. Address stress and fear deliberately. Sleep, emotional expression, somatic tracking and pacing within safe limits can reduce both the neuroplastic layer and, possibly, the stress load on the immune system. Our guide to flare plans can be adapted for MG.

This article is for general education and is not medical advice, and it does not diagnose or treat any condition. Persistent symptoms deserve a proper medical assessment to rule out disease or injury before a neuroplastic explanation is considered. If your symptoms are new, changing, or come with red-flag signs such as fever, unexplained weight loss, numbness or weakness, chest pain, or loss of bladder or bowel control, see a clinician promptly.